Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAggressive LymphomasIndolent LymphomasTransplantationDiseaseHodgkin LymphomaMantle Cell LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, Lymphoplasmocytic / Waldenström's diseaseNHL, B-Cell Type, Marginal Zone LymphomaStem Cell Transplantation, AutologousSubgroupICD10C81.-C82.-C82.7C82.9C83.0C83.1C83.3C88.0-Z94.80MeSHHodgkin DiseaseTransplantation, AutologousSequenceChemotherapyChemo-substanceCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabChemo-substanceCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabChemo-substanceCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabChemo-substanceCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabNo. Substances6 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionBendamustineCarmustineCiprofloxacinCotrimoxazoleCytarabineDexamethasoneDimetindenEtoposideFosaprepitantGranisetronMelphalanParacetamolPegfilgrastimThiotepaValaciclovirSupportive substanceBalanced Crystalloid SolutionBendamustineCarmustineCiprofloxacinCotrimoxazoleCytarabineDexamethasoneDimetindenEtoposideFosaprepitantGranisetronMelphalanParacetamolPegfilgrastimThiotepaValaciclovirSupportive substanceBalanced Crystalloid SolutionBendamustineCarmustineCiprofloxacinCotrimoxazoleCytarabineDexamethasoneDimetindenEtoposideFosaprepitantGranisetronMelphalanParacetamolPegfilgrastimThiotepaValaciclovirSupportive substanceBalanced Crystalloid SolutionBendamustineCarmustineCiprofloxacinCotrimoxazoleCytarabineDexamethasoneDimetindenEtoposideFosaprepitantGranisetronMelphalanParacetamolPegfilgrastimThiotepaValaciclovirNo. Substances611Protocol classificationTherapy classificationalternativecurrent standardIntensityHochdosis, bei autologer SZTStandard doseTherapy indicationRelapse therapyseveral possibleTherapy phaseautologous stem cell transplantationSalvageTherapy intentioncurativeRisksDiarrheaEmetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityHepatotoxicityInfectionsMucositisOral MucositisPyrexia only studiesPublicationAuthorCaballero MDDuléry RKeil FKirschey SDiseaseNHL, HL, Rezidiv, fehlende Remission nach kurativer ChemotherapieNHL oder HL, auto-SZTRefraktäres oder rezidivierendes NHL oder HLrezidivierte aggressive B-NHL, 18-65 Jahre, ECOG 0-2Origin3rd Medical Department for Haematology and Oncology, Hanusch Hospital, Vienna, AustriaCentre de Recherche Saint-Antoine, Sorbonne University, Paris, FranceDepartment of Haematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University MainzDepartment of Hematology, Hospital Universitario Salamanca, SpanienProtokolle in Überarbeitung 4 protocols foundRevision: BEAM - Carmustin 300 / Etoposid 200 / Cytarabin 200 / Melphalan 140, autologe Stammzelltransplantation (PID280 V2.2)Revision: BeEAM - Bendamustin 200 / Etoposid 100 / Cytarabin 200 / Melphalan 140, autologe Stammzelltransplantation (PID879 V1.1)R-DexaBEAM - Rituximab 375 / Dexamethasone 8 / Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 20, B-Non-Hodgkin Lymphoma (PID1006 V1.0)Revision: TEAM - Thiotepa 8 / Etoposid 100 / Cytarabin 200 / Melphalan 200, autologe Stammzelltransplantation (PID406 V2.1)
